'We're going to miss the next Keytruda': Lilly CEO warns of IRA
The IRA's price-setting measures stand to cut ideas like Keytruda before they can "even grow roots," Eli Lilly CEO David Ricks said at a PhRMA panel.
Source: fiercepharma.com
Stay updated with breaking news from Steven Ubl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The IRA's price-setting measures stand to cut ideas like Keytruda before they can "even grow roots," Eli Lilly CEO David Ricks said at a PhRMA panel.
Since 2012, profit from the two sources has eclipsed the value of rebates paid to PBMs by pharma companies.